Ann: Paradigm to present at Virtual Conference, Friday 27th March, page-23

Mozz's Notes from Conference:

I'm breaking this into parts as I have so many notes! My sound feed was terrible so I might've missed bits ...others that attened do post your comments, doesn't matter if there is overlap..

Other Parts to come throughout day...


PART 1
Hmm lots of info...most of it we know but I have a few points to begin with...

1) Paul started with general intro of the company and that we have a re purposed drug etc
2) PAR is suitably geared up to continue business throughout Covid-19 outbreak, its business usual and it isn't a major barrier to PAR.
3) PAR have been working from home for last 3 weeks, no issues and no slow down in work from their end.
4) PAR has a low burn rate of cash and are mindful of expenses.
5) Minutes of Pre Ind to be issued shortly, there is delay from FDA side.
6) FDA meeting with FDA (Pre Ind) was very positive and informative. "there is "..great strength of having the Bene product"
7) Paul quote "My take is that it is almost impossible for another company to produce a similar drug"
(Mozz Notes, this is due to complexity and bio signature required by FDA )

..more to come soon...